Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P485: AZACITIDINE, VENETOCLAX...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

Bibliographic Details
Main Authors: Nicholas Short, Walid Macaron, Courtney Dinardo, Naval Daver, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Ghayas Issa, Koji Sasaki, Jan Burger, Abhishek Maiti, Yesid Alvarado, Jennifer Thankachan, Regina Abramova, Lewis Nasr, Cedric Nasnas, Marianne Zoghbi, Tapan Kadia, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000968848.53526.0f
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000968848.53526.0f

Similar Items

  • Acute myeloid leukemia: current progress and future directions
    by: Hagop Kantarjian, et al.
    Published: (2021-02-01)
  • S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
    by: Nicholas Short, et al.
    Published: (2023-08-01)
  • A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
    by: Nicholas J. Short, et al.
    Published: (2023-07-01)
  • P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    by: Fadi Haddad, et al.
    Published: (2023-08-01)
  • P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
    by: S. P. Desikan, et al.
    Published: (2022-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs